menu
    • menu
    [{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Alpheus Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Alpheus Medical","highestDevelopmentStatusID":"6","companyTruncated":"Alpheus Medical \/ Alpheus Medical"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Alpheus Medical

    Menu

    Alpheus Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alpheus Medical

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Alpheus Medical

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alpheus Announces Positive Glioma Treatment Phase 1/2 Results

                            Details : Low-Intensity Diffuse Ultrasound with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA) is being investigated in patients with recurrent or refractory high-grade gliomas.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 24, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alpheus Medical

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Alpheus Medical

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Universität Münster

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound fo...

                            Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Astrocytoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Universität Münster

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alpheus Medical

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Alpheus Medical

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

                            Details : 5-aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 05, 2022

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth